UBX logo

Unity Biotechnology (UBX) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

03 May 2018

Indexes:

Not included

Description:

Unity Biotechnology focuses on developing therapies to slow or reverse age-related diseases. The company aims to improve healthspan by targeting cellular senescence, which contributes to aging and age-related conditions. Their innovative approach seeks to enhance the quality of life for older adults through advanced biotechnology solutions.

Events Calendar

Earnings

Next earnings date:

Apr 15, 2025

Recent quarterly earnings:

Nov 04, 2024

Recent annual earnings:

Apr 15, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Oct 20, 2022

Analyst ratings

Recent major analysts updates

08 Aug '24 HC Wainwright & Co.
Buy
15 May '24 HC Wainwright & Co.
Buy
16 Apr '24 HC Wainwright & Co.
Buy
16 Nov '23 Wedbush
Outperform
14 Nov '23 HC Wainwright & Co.
Buy
09 Aug '23 HC Wainwright & Co.
Buy
26 June '23 Wedbush
Neutral
31 May '23 Roth MKM
Buy
26 May '23 Citigroup
Buy
10 May '23 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates
UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates
UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates
UBX
globenewswire.com04 November 2024

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2024.

UNITY Biotechnology (UBX) Upgraded to Buy: Here's What You Should Know
UNITY Biotechnology (UBX) Upgraded to Buy: Here's What You Should Know
UNITY Biotechnology (UBX) Upgraded to Buy: Here's What You Should Know
UBX
zacks.com09 August 2024

UNITY Biotechnology (UBX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates
UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates
UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates
UBX
globenewswire.com06 August 2024

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2024.

UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer
UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer
UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer
UBX
globenewswire.com22 July 2024

SAN FRANCISCO, July 22, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the appointment of Alicia Tozier, MBA, as chief strategy officer. In this new role, she will develop and implement the company's corporate and product strategies.

All You Need to Know About UNITY Biotechnology (UBX) Rating Upgrade to Buy
All You Need to Know About UNITY Biotechnology (UBX) Rating Upgrade to Buy
All You Need to Know About UNITY Biotechnology (UBX) Rating Upgrade to Buy
UBX
zacks.com17 May 2024

There is increasing optimism about UNITY Biotechnology's earnings prospects, leading to its upgrade to a Zacks Rank #2 (Buy) and potential for a rise in stock price.

Unity (UNX) Down on Disappointing Results From Wet AMD Study
Unity (UNX) Down on Disappointing Results From Wet AMD Study
Unity (UNX) Down on Disappointing Results From Wet AMD Study
UBX
Zacks Investment Research28 March 2023

Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD study.

Why Is Unity Biotechnology (UBX) Stock Down 52% Today?
Why Is Unity Biotechnology (UBX) Stock Down 52% Today?
Why Is Unity Biotechnology (UBX) Stock Down 52% Today?
UBX
InvestorPlace27 March 2023

Unity Biotechnology (NASDAQ: UBX ) stock is taking a beating on Monday after revealing results from its Phase 2 clinical trial of UBX1325. UBX1325 is a treatment in development by the company that it's testing for use with patients suffering from wet age-related macular degeneration ( AMD ).

FAQ

  • What is the primary business of Unity Biotechnology?
  • What is the ticker symbol for Unity Biotechnology?
  • Does Unity Biotechnology pay dividends?
  • What sector is Unity Biotechnology in?
  • What industry is Unity Biotechnology in?
  • What country is Unity Biotechnology based in?
  • When did Unity Biotechnology go public?
  • Is Unity Biotechnology in the S&P 500?
  • Is Unity Biotechnology in the NASDAQ 100?
  • Is Unity Biotechnology in the Dow Jones?
  • When was Unity Biotechnology's last earnings report?
  • When does Unity Biotechnology report earnings?
  • Should I buy Unity Biotechnology stock now?

What is the primary business of Unity Biotechnology?

Unity Biotechnology focuses on developing therapies to slow or reverse age-related diseases. The company aims to improve healthspan by targeting cellular senescence, which contributes to aging and age-related conditions. Their innovative approach seeks to enhance the quality of life for older adults through advanced biotechnology solutions.

What is the ticker symbol for Unity Biotechnology?

The ticker symbol for Unity Biotechnology is NASDAQ:UBX

Does Unity Biotechnology pay dividends?

No, Unity Biotechnology does not pay dividends

What sector is Unity Biotechnology in?

Unity Biotechnology is in the Healthcare sector

What industry is Unity Biotechnology in?

Unity Biotechnology is in the Biotechnology industry

What country is Unity Biotechnology based in?

Unity Biotechnology is headquartered in United States

When did Unity Biotechnology go public?

Unity Biotechnology's initial public offering (IPO) was on 03 May 2018

Is Unity Biotechnology in the S&P 500?

No, Unity Biotechnology is not included in the S&P 500 index

Is Unity Biotechnology in the NASDAQ 100?

No, Unity Biotechnology is not included in the NASDAQ 100 index

Is Unity Biotechnology in the Dow Jones?

No, Unity Biotechnology is not included in the Dow Jones index

When was Unity Biotechnology's last earnings report?

Unity Biotechnology's most recent earnings report was on 4 November 2024

When does Unity Biotechnology report earnings?

The next expected earnings date for Unity Biotechnology is 15 April 2025

Should I buy Unity Biotechnology stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions